BMY-14802 protects against ischemia-induced neuronal damage in the gerbil.

Abstract

BMY-14802, a selective sigma ligand currently under investigation as an atypical antipsychotic agent, was tested for potential anti-ischemic activity. BMY-14802 (10, 30 and 50 mg/kg) did not produce any stereotyped behavior, ataxia or seizures. When gerbils were pretreated with 10, 30 or 50 mg/kg of BMY-14802 30 min prior to bilateral occlusion of carotid arteries for 5 min, BMY-14802 significantly protected against ischemia-induced neuronal loss in the hippocampus. Thus, BMY-14802 may also be useful as an anti-ischemic agent that does not produce psychotomimetic effects.

• Authors: P C Contreras, N M Gray, D M Ragan, T H Lanthorn
• Journal: Life sciences (Life Sci) Vol. 51 Issue 14 Pg. 1145-9 ( 1992) ISSN: 0024-3205 [Print] Netherlands
• PMID: 1518377 (Publication Type: Journal Article)

Chemical References

• Psychotropic Drugs
• Pyrimidines
• alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol

Topics

• Animals
• Behavior, Animal (drug effects)
• Brain Ischemia (drug therapy, pathology)
• Carotid Arteries
• Gerbillinae
• Hippocampus (drug effects, pathology)
• Neurons (drug effects, pathology)
• Psychotropic Drugs (pharmacology)
• Pyrimidines (pharmacology)